^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Synovial Sarcoma

    Apply
    Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 (NCT02650986)
    Phase 1/2
    Roswell Park Cancer Institute
    Active, not recruiting
    Last update posted :
    06/13/2024
    Initiation :
    07/14/2017
    Primary completion :
    03/04/2021
    Completion :
    07/14/2032
    BRAF • CTAG1B
    |
    BRAF mutation
    |
    azacitidine • cyclophosphamide • decitabine • cyclophosphamide intravenous
    A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors (NCT05848739)
    Phase 1
    Sapience Therapeutics
    Recruiting
    Last update posted :
    06/05/2024
    Initiation :
    06/05/2023
    Primary completion :
    05/31/2026
    Completion :
    05/31/2027
    PD-L1 • MSI • BRCA
    |
    PD-L1 expression • MSI-H/dMMR • BRCA mutation
    |
    Avastin (bevacizumab) • 5-fluorouracil • irinotecan • Fruzaqla (fruquintinib) • leucovorin calcium • ST316
    Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1 (NCT06083883)
    Phase 1
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    06/04/2024
    Initiation :
    03/27/2024
    Primary completion :
    11/30/2026
    Completion :
    11/30/2028
    HLA-A • CTAG1B • SSX1
    |
    HLA-A*02
    |
    cyclophosphamide • fludarabine IV
    A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma (NCT02601950)
    Phase 2
    Epizyme, Inc.
    Completed
    Last update posted :
    04/29/2024
    Initiation :
    12/22/2015
    Primary completion :
    02/26/2024
    Completion :
    02/26/2024
    CD34 • SS18
    |
    SMARCA4 mutation
    |
    Tazverik (tazemetostat)
    SPEARHEAD-3 Pediatric Study (NCT05642455)
    Phase 1/2
    Adaptimmune
    Recruiting
    Last update posted :
    04/24/2024
    Initiation :
    09/01/2023
    Primary completion :
    10/01/2026
    Completion :
    07/30/2038
    HLA-A • MAGEA4
    |
    HLA-A*02 • HLA-A2 positive • MAGEA4 expression
    |
    Tecelra (afamitresgene autoleucel)
    B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults (STRIvE-02) (NCT04483778)
    Phase 1
    Seattle Children's Hospital
    Active, not recruiting
    Last update posted :
    04/23/2024
    Initiation :
    07/13/2020
    Primary completion :
    12/01/2025
    Completion :
    12/01/2040
    CD276
    |
    CD276 expression • CD19 expression
    |
    Keytruda (pembrolizumab) • SCRI-CARB7H3(s) • SCRI-CARB7H3(s)x19 • SCRI-huCAR19v1
    EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults (STRIvE-01) (NCT03618381)
    Phase 1
    Seattle Children's Hospital
    Recruiting
    Last update posted :
    04/09/2024
    Initiation :
    06/18/2019
    Primary completion :
    06/01/2025
    Completion :
    06/01/2040
    EGFR
    |
    EGFR expression
    |
    EGFR806-specific CAR T-cell therapy • SCRI-CARB7H3(s)x19 • SCRI-huCAR19v1
    Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma (SPEARHEAD-1) (NCT04044768)
    Phase 2
    Adaptimmune
    Recruiting
    Last update posted :
    02/19/2024
    Initiation :
    08/13/2019
    Primary completion :
    10/10/2021
    Completion :
    04/01/2038
    HLA-A • MAGEA4
    |
    HLA-A*02 • MAGEA4 expression
    |
    Tecelra (afamitresgene autoleucel)
    HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma (NCT04995003)
    Phase 1
    Baylor College of Medicine
    Recruiting
    Last update posted :
    01/25/2024
    Initiation :
    12/07/2021
    Primary completion :
    12/31/2027
    Completion :
    12/31/2040
    HER-2
    |
    HER-2 positive • HER-2 expression
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • cyclophosphamide • fludarabine IV
    MAGE-A4ᶜ¹º³²T for Multi-Tumor (NCT03132922)
    Phase 1
    Adaptimmune
    Active, not recruiting
    Last update posted :
    01/22/2024
    Initiation :
    05/15/2017
    Primary completion :
    12/27/2022
    Completion :
    09/01/2032
    HLA-A • MAGEA4
    |
    HLA-A*02 • HLA-A2 positive
    |
    Tecelra (afamitresgene autoleucel)
    START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer (NCT05492682)
    Phase 1
    Valo Therapeutics Oy
    Recruiting
    Last update posted :
    01/12/2024
    Initiation :
    02/02/2023
    Primary completion :
    06/01/2025
    Completion :
    09/01/2025
    PD-L1
    |
    Keytruda (pembrolizumab) • cyclophosphamide • PeptiCRAd-1
    Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors (NCT02869217)
    Phase 1
    University Health Network, Toronto
    Active, not recruiting
    Last update posted :
    12/08/2023
    Initiation :
    09/01/2016
    Primary completion :
    09/01/2024
    Completion :
    09/01/2024
    HLA-A • CTAG1B
    |
    HLA-A*02 • CTAG1B expression
    |
    cyclophosphamide • fludarabine IV • mipetresgene autoleucel (TBI-1301) • cyclophosphamide intravenous
    Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced Autologous T Lymphocytes) in Patients With Synovial Sarcoma (NCT03250325)
    Phase 1/2
    Takara Bio Inc.
    Completed
    Last update posted :
    12/06/2023
    Initiation :
    09/20/2017
    Primary completion :
    01/23/2020
    Completion :
    03/09/2022
    HLA-A • CTAG1B
    |
    HLA-A*02 • CTAG1B expression
    |
    cyclophosphamide • mipetresgene autoleucel (TBI-1301) • cyclophosphamide intravenous
    Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision) (NCT06094101)
    Phase 1/2
    University Hospital Tuebingen
    Recruiting
    Last update posted :
    11/22/2023
    Initiation :
    09/19/2023
    Primary completion :
    06/01/2027
    Completion :
    09/01/2027
    CD8 • CD4
    Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma (NCT03063632)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    10/25/2023
    Initiation :
    12/14/2017
    Primary completion :
    04/08/2021
    Completion :
    03/14/2023
    IFNG • CTAG1B
    |
    CTAG1B expression
    |
    Keytruda (pembrolizumab) • Actimmune (interferon gamma-1 b) • Pembroria (pembrolizumab biosimilar)
    Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma (NCT05993299)
    Phase 2
    GlaxoSmithKline
    Active, not recruiting
    Last update posted :
    10/16/2023
    Initiation :
    12/31/2019
    Primary completion :
    10/12/2022
    Completion :
    07/01/2024
    HLA-A • CTAG1B
    |
    HLA-A*02:01 • HLA-A*02 • CTAG1B expression • HLA-A2 positive
    |
    cyclophosphamide • fludarabine IV • letetresgene autoleucel (GSK3377794)
    Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma (NCI-2018-00926) (NCT03450122)
    Phase 1
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    10/16/2023
    Initiation :
    09/13/2018
    Primary completion :
    12/06/2022
    Completion :
    12/06/2022
    HLA-A • CTAG1B
    |
    cyclophosphamide • Proleukin (aldesleukin) • CMB305 • ID-LV305 • cyclophosphamide intravenous
    Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery (NCT03009201)
    Phase 1b
    OHSU Knight Cancer Institute
    Completed
    Last update posted :
    08/16/2023
    Initiation :
    03/10/2017
    Primary completion :
    10/08/2019
    Completion :
    06/30/2023
    RB1
    |
    doxorubicin hydrochloride • Kisqali (ribociclib)
    Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma (NCT02452554)
    Phase 2
    Children's Oncology Group
    Completed
    Last update posted :
    01/13/2022
    Initiation :
    10/12/2015
    Primary completion :
    06/30/2017
    Completion :
    09/30/2021
    NCAM1
    |
    NCAM1 expression
    |
    lorvotuzumab mertansine (IMGN901)
    A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma (NCT02601937)
    Phase 1
    Epizyme, Inc.
    Completed
    Last update posted :
    12/27/2021
    Initiation :
    01/07/2016
    Primary completion :
    10/22/2021
    Completion :
    10/22/2021
    SS18
    |
    SMARCA4 mutation
    |
    Tazverik (tazemetostat)
    A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma (ADP 04511) (NCT01343043)
    Phase 1
    GlaxoSmithKline
    Completed
    Last update posted :
    06/30/2021
    Initiation :
    09/27/2012
    Primary completion :
    06/18/2019
    Completion :
    06/18/2019
    HLA-A • CTAG1B
    |
    HLA-A*02 • CTAG1B expression
    |
    cyclophosphamide • fludarabine IV • letetresgene autoleucel (GSK3377794)
    Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies (NCT03638206)
    Phase 1/2
    Shenzhen BinDeBio Ltd.
    Recruiting
    Last update posted :
    12/11/2019
    Initiation :
    03/01/2018
    Primary completion :
    03/01/2023
    Completion :
    03/01/2023
    MET • CD19 • HLA-A • MSLN • CD22 • CD33 • CTAG1B
    |
    HLA-A*02:01 • CD19 expression • HLA-A positive
    |
    cyclophosphamide • CAR-T cell immunotherapy • multi-target gene-modified CAR-T/TCR-T cell immunotherapy
    Comparison of Filgrastim and Filgrastim SD/01in Boosting White Cell Counts After Intensive Chemotherapy (NCT00004853)
    Phase 1
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    11/12/2019
    Initiation :
    03/03/2000
    Primary completion :
    05/20/2009
    Completion :
    05/20/2009
    CD34
    |
    CD34 positive
    |
    Neupogen (filgrastim)
    Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a (NCT03697824)
    Phase 1b/2a
    GlaxoSmithKline
    Withdrawn
    Last update posted :
    10/29/2019
    Initiation :
    02/25/2019
    Primary completion :
    07/18/2022
    Completion :
    07/18/2022
    HLA-A • CTAG1B • CTAG2
    |
    HLA-A*02 • CTAG2 expression
    |
    Keytruda (pembrolizumab) • cyclophosphamide • fludarabine IV • letetresgene autoleucel (GSK3377794) • cyclophosphamide intravenous
    Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma (NCT01614795)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    12/11/2018
    Initiation :
    06/18/2012
    Primary completion :
    04/01/2014
    Completion :
    04/01/2014
    mTOR • IR
    |
    Torisel (temsirolimus) • cixutumumab (IMC A12)
    T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies (NCT02457650)
    Phase 1
    Shenzhen Second People's Hospital
    Unknown status
    Last update posted :
    08/03/2016
    Initiation :
    04/01/2015
    Primary completion :
    12/01/2019
    Completion :
    12/01/2019
    CTAG1B
    |
    CTAG1B expression • HLA-A2 positive
    |
    cyclophosphamide • fludarabine IV • cyclophosphamide intravenous
    NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma (NCT02059850)
    Phase 1
    Fred Hutchinson Cancer Center
    Withdrawn
    Last update posted :
    02/03/2016
    Initiation :
    07/01/2014
    Primary completion :
    01/01/2016
    Completion :
    01/01/2016
    CTAG1B
    |
    CTAG1B expression
    |
    cyclophosphamide • cyclophosphamide intravenous
    Autologous T Cells and Cyclophosphamide in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery (NCT01477021)
    Phase 1
    Fred Hutchinson Cancer Center
    Completed
    Last update posted :
    12/11/2014
    Initiation :
    01/01/2012
    Primary completion :
    09/01/2013
    CTAG1B
    |
    CTAG1B expression
    |
    cyclophosphamide • cyclophosphamide intravenous